About
Copy Link
Titles
Manager, IT
Departments & Organizations
- Anticevic Lab
- Cho Lab
Research
Copy Link
Research at a Glance
Yale Co-Authors
Frequent collaborators of Zailyn Tamayo's published research.
Publications Timeline
A big-picture view of Zailyn Tamayo's research output by year.
Scott Woods, MD
Albert Powers, MD, PhD
Clara Fonteneau, PhD
Godfrey Pearlson, MA, MBBS
John Krystal, MD
Nicole Popp Santamauro, MA
18Publications
140Citations
Publications
2025
A translational neuroscience & computational evaluation of a D1R partial agonist for schizophrenia (TRANSCENDS): Rationale and study design of a brain-based clinical trial
Fonteneau C, Tamayo Z, Price A, Pan L, Afriyie-Agyemang Y, Agrawal S, Butler A, Cail C, Calkins M, Chakilam S, Forselius-Bielen K, Fram G, Frazier A, Gil R, Govil P, Gray D, Grinband J, Gur R, Haubold N, Heffernan Z, Heneks M, Kegeles L, Kohler C, Lin C, Lu J, Mayer M, Pham P, Perlman G, Rahmati M, Ranganathan M, Santamauro N, Schutte C, Selloni A, Van Snellenberg J, Surti T, Wolf D, Zharyy C, Group T, Abi-Dargham A, Gur R, Lieberman J, Kantrowitz J, Anticevic A, Cho Y, Krystal J. A translational neuroscience & computational evaluation of a D1R partial agonist for schizophrenia (TRANSCENDS): Rationale and study design of a brain-based clinical trial. Journal Of Psychiatric Research 2025 DOI: 10.1016/j.jpsychires.2025.12.020.Peer-Reviewed Original ResearchConceptsPartial agonistCognitive impairmentSpatial working memoryDouble-blind doseWorking memoryD1/D5 receptorsFunctional neuroimagingNeural mechanismsSchizophreniaTranslational neuroscienceCognitive paradigmNeural circuitsUntreated symptomsD1RDecades of researchFMRIClinical trialsMicro-circuitryNeuroscienceAgonistsImpairmentStudy designD1/D5Clinical dataNeuroimagingCollecting language, speech acoustics, and facial expression to predict psychosis and other clinical outcomes: strategies from the AMP® SCZ initiative
Bilgrami Z, Castro E, Agurto C, Liebenthal E, Ennis M, Baker J, Scott I, Colton B, Cho K, Li L, Tamayo Z, Henecks M, Rahimi Eichi H, Henry T, Addington J, Alameda L, Arango C, Breitborde N, Broome M, Cadenhead K, Calkins M, Chen E, Choi J, Conus P, Cornblatt B, Ellman L, Fusar-Poli P, Gaspar P, Gerber C, Glenthøj L, Horton L, Hui C, Kambeitz J, Kambeitz-Ilankovic L, Keshavan M, Kim S, Koutsouleris N, Kwon J, Langbein K, Mamah D, Diaz-Caneja C, Mathalon D, Mittal V, Nordentoft M, Pearlson G, Perez J, Perkins D, Powers A, Rogers J, Sabb F, Schiffman J, Shah J, Silverstein S, Smesny S, Stone W, Yassin W, Strauss G, Thompson J, Upthegrove R, Verma S, Wang J, Wolf D, McGorry P, Kahn R, Kane J, Anticevic A, Bearden C, Dwyer D, Billah T, Bouix S, Pasternak O, Shenton M, Woods S, Nelson B, Cecchi G, Corcoran C, Wolff P. Collecting language, speech acoustics, and facial expression to predict psychosis and other clinical outcomes: strategies from the AMP® SCZ initiative. Schizophrenia 2025, 11: 125. PMID: 41093845, PMCID: PMC12528486, DOI: 10.1038/s41537-025-00669-z.Peer-Reviewed Original ResearchCitationsAltmetricConceptsClinical high riskSample taskEarly psychosisClinical high-risk participantsFacial expressionsCommunity controlsSpeech-based detectionDetection of psychosisPsychosis riskReferential languagePsychosisSyntactic embeddingElicitation conditionsNatural language processing parserEveryday speechSpeech acousticsInterviewer trainingMachine-learning classifiersSpeechLanguage modelElevated useComputational linguisticsTaskData integrationLanguageA common symptom geometry of mood improvement under sertraline and placebo associated with distinct neural patterns
Berkovitch L, Lee K, Ji J, Helmer M, Rahmati M, Demsar J, Kraljic A, Matkovic A, Tamayo Z, Murray J, Repovs G, Krystal J, Martin W, Fonteneau C, Anticevic A. A common symptom geometry of mood improvement under sertraline and placebo associated with distinct neural patterns. Psychological Medicine 2025, 55: e185. PMID: 40611472, PMCID: PMC12270277, DOI: 10.1017/s0033291725100962.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsMechanisms of Major depressive disordersGlobal brain connectivitySymptom improvementClinical Global Impression ScaleGlobal Impression ScaleMajor depressive disorderManic-like symptomsMeasures of clinical improvementAntidepressant treatmentImpression ScaleDepressive disorderNeural profilesMood improvementSuicidal ideasPattern of clinical improvementSymptom ScaleClinical scalesNeural patternsSertralineBrain connectivityNeural circuitsIndividual itemsPatients' scoresClinical improvementImproved scoresThe electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures
Mathalon D, Nicholas S, Roach B, Billah T, Lavoie S, Whitford T, Hamilton H, Addamo L, Anohkin A, Bekinschtein T, Belger A, Buccilli K, Cahill J, Carrión R, Damiani S, Dzafic I, Ebdrup B, Izyurov I, Jarcho J, Jenni R, Jo A, Kerins S, Lee C, Martin E, Mayol-Troncoso R, Niznikiewicz M, Parvaz M, Pogarell O, Prieto-Montalvo J, Rabin R, Roalf D, Rogers J, Salisbury D, Shaik R, Shankman S, Stevens M, Suen Y, Swann N, Tang X, Thompson J, Tso I, Wenzel J, Zhou J, Addington J, Alameda L, Arango C, Breitborde N, Broome M, Cadenhead K, Calkins M, Castillo-Passi R, Chen E, Choi J, Conus P, Corcoran C, Cornblatt B, Diaz-Caneja C, Ellman L, Fusar-Poli P, Gaspar P, Gerber C, Glenthøj L, Horton L, Hui C, Kambeitz J, Kambeitz-Ilankovic L, Keshavan M, Kim M, Kim S, Koutsouleris N, Kwon J, Langbein K, Mamah D, Mittal V, Nordentoft M, Pearlson G, Perez J, Perkins D, Powers A, Sabb F, Schiffman J, Shah J, Silverstein S, Smesny S, Stone W, Strauss G, Upthegrove R, Verma S, Wang J, Wolf D, Zhang T, Bouix S, Pasternak O, Cho K, Coleman M, Dwyer D, Nunez A, Tamayo Z, Wood S, Kahn R, Kane J, McGorry P, Bearden C, Nelson B, Woods S, Shenton M, Light G. The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures. Schizophrenia 2025, 11: 85. PMID: 40480970, PMCID: PMC12144291, DOI: 10.1038/s41537-025-00622-0.Peer-Reviewed Original ResearchCitationsAltmetricConceptsEvent-related oscillationsEEG power spectral densityClinical outcomesMarkers of illness progressionRisks of antipsychotic drugsAuditory steady state responsePredictor of clinical outcomeMismatch negativityVariable clinical outcomesControlled clinical trialsClinical high riskTest-retest reliabilitySecondary outcome measuresEEG-based measuresVisual P300Antipsychotic drugsPaired t-testEEG protocolsClinical trialsEffective medicationsInterim analysisHigh riskPersonalized treatmentTraditional frequency bandsCHR individualsDigital health technologies in the accelerating medicines Partnership® Schizophrenia Program
Wigman J, Ching A, Chung Y, Eichi H, Lane E, Langholm C, Vaidyam A, Byun A, Haidar A, Hartmann J, Nunez A, Dwyer D, Nasarudin A, Borders O, Scott I, Tamayo Z, Matneja P, Cho K, Addington J, Alameda L, Arango C, Breitborde N, Broome M, Cadenhead K, Calkins M, Chen E, Choi J, Conus P, Corcoran C, Cornblatt B, Diaz-Caneja C, Ellman L, Fusar-Poli P, Gaspar P, Gerber C, Glenthøj L, Horton L, Hui C, Kambeitz J, Kambeitz-Ilankovic L, Keshavan M, Kim S, Koutsouleris N, Langbein K, Mamah D, Mathalon D, Mittal V, Nordentoft M, Pearlson G, Perez J, Perkins D, Powers A, Rogers J, Sabb F, Schiffman J, Shah J, Silverstein S, Smesny S, Yassin W, Stone W, Strauss G, Thompson J, Upthegrove R, Verma S, Wang J, Wolf D, Wolff P, Rowland L, D’Alfonso S, Pasternak O, Bouix S, McGorry P, Kahn R, Kane J, Bearden C, Woods S, Shenton M, Nelson B, Baker J, Torous J. Digital health technologies in the accelerating medicines Partnership® Schizophrenia Program. Schizophrenia 2025, 11: 83. PMID: 40461469, PMCID: PMC12134270, DOI: 10.1038/s41537-025-00599-w.Peer-Reviewed Original ResearchCitationsAltmetricConceptsDigital componentsDigital health technologiesSmartphone-based digital phenotypingNovel digital health technologiesClinical high riskDigital phenotypingDigital dataHealth technologiesPredictive of transition to psychosisReal-life experiencesSchizophrenia ProgramDaily lifeTransition to psychosisPassive dataEpisode of psychosisPsychosis transitionMapping of experiencesTechnologyHigh riskMeta-analytic studiesCollaborative project533. Bold Signal Can Capture Individual Variability in Spatial Working Memory Deficits Induced by Ketamine
Rahmati M, Moujaes F, Purg N, Fonteneau C, Santamauro N, Tamayo Z, Repovs G, Preller K, Anticevic A, Fineberg S, Murray J, Krystal J, Cho Y. 533. Bold Signal Can Capture Individual Variability in Spatial Working Memory Deficits Induced by Ketamine. Biological Psychiatry 2025, 97: s317. DOI: 10.1016/j.biopsych.2025.02.772.Peer-Reviewed Original Research541. Identifying Neurobiological Mechanisms of Psychosis-Risk
Brege S, Lee K, Tamayo Z, Grent-'t-Jong T, Anticevic A, Uhlhaas P, Cho Y, Fonteneau C. 541. Identifying Neurobiological Mechanisms of Psychosis-Risk. Biological Psychiatry 2025, 97: s321. DOI: 10.1016/j.biopsych.2025.02.780.Peer-Reviewed Original Research478. Cross-Site Quality Assessment of Data From a Pharmacologic Neuroimaging Trial Targeting Working Memory Neural Circuits in Schizophrenia
Zharyy C, Fonteneau C, Rahmati M, Price A, Gil R, Govil P, Grinband J, Gur R, Haubold N, Heffernan Z, Lu J, Mayer M, Ranganathan M, Santamauro N, Tamayo Z, Van Snellenberg J, Wolf D, Group T, Anticevic A, Lieberman J, Kantrowitz J, Abi-Dargham A, Gur R, Krystal J, Cho Y. 478. Cross-Site Quality Assessment of Data From a Pharmacologic Neuroimaging Trial Targeting Working Memory Neural Circuits in Schizophrenia. Biological Psychiatry 2025, 97: s294. DOI: 10.1016/j.biopsych.2025.02.716.Peer-Reviewed Original ResearchConceptsEnabling FAIR data stewardship in complex international multi-site studies: Data Operations for the Accelerating Medicines Partnership® Schizophrenia Program
Billah T, Cho K, Borders O, Chung Y, Ennis M, Jacobs G, Liebenthal E, Mathalon D, Mohandass D, Nicholas S, Pasternak O, Penzel N, Eichi H, Wolff P, Anticevic A, Laulette K, Nunez A, Tamayo Z, Buccilli K, Colton B, Dwyer D, Hendricks L, Yuen H, Spark J, Tod S, Carrington H, Chen J, Coleman M, Corcoran C, Haidar A, John O, Kelly S, Marcy P, Matneja P, McGowan A, Ray S, Veale S, Winter-Van Rossum I, Addington J, Allott K, Calkins M, Clark S, Gur R, Harms M, Perkins D, Ruparel K, Stone W, Torous J, Yung A, Zoupou E, Fusar-Poli P, Mittal V, Shah J, Wolf D, Cecchi G, Kapur T, Kubicki M, Lewandowski K, Bearden C, McGorry P, Kahn R, Kane J, Nelson B, Woods S, Shenton M, Baker J, Bouix S. Enabling FAIR data stewardship in complex international multi-site studies: Data Operations for the Accelerating Medicines Partnership® Schizophrenia Program. Schizophrenia 2025, 11: 55. PMID: 40180978, PMCID: PMC11968805, DOI: 10.1038/s41537-025-00560-x.Peer-Reviewed Original ResearchCitationsAltmetricConceptsData flowSensitive health informationResearch communityClose-to-real-timeData governance modelData operationsSeamless data flowArchiving platformControl protocolData dictionaryData visualizationOperator ecosystemParticipant privacyQuality assessmentData stewardshipData capture systemData setsHealth informationDataData qualityProcess-oriented approachData acquisitionResearch managementCollected dataPrivacyThe MR neuroimaging protocol for the Accelerating Medicines Partnership® Schizophrenia Program
Harms M, Cho K, Anticevic A, Bolo N, Bouix S, Campbell D, Cannon T, Cecchi G, Goncalves M, Haidar A, Hughes D, Izyurov I, John O, Kapur T, Kim N, Kotler E, Kubicki M, Kuperman J, Laulette K, Lindberg U, Markiewicz C, Ning L, Poldrack R, Rathi Y, Romo P, Tamayo Z, Wannan C, Wickham A, Yassin W, Zhou J, Addington J, Alameda L, Arango C, Breitborde N, Broome M, Cadenhead K, Calkins M, Chen E, Choi J, Conus P, Corcoran C, Cornblatt B, Diaz-Caneja C, Ellman L, Fusar-Poli P, Gaspar P, Gerber C, Glenthøj L, Horton L, Hui C, Kambeitz J, Kambeitz-Ilankovic L, Keshavan M, Kim S, Koutsouleris N, Kwon J, Langbein K, Mamah D, Mathalon D, Mittal V, Nordentoft M, Pearlson G, Perez J, Perkins D, Powers A, Rogers J, Sabb F, Schiffman J, Shah J, Silverstein S, Smesny S, Stone W, Strauss G, Thompson J, Upthegrove R, Verma S, Wang J, Wolf D, Kahn R, Kane J, McGorry P, Nelson B, Woods S, Shenton M, Wood S, Bearden C, Pasternak O. The MR neuroimaging protocol for the Accelerating Medicines Partnership® Schizophrenia Program. Schizophrenia 2025, 11: 52. PMID: 40175382, PMCID: PMC11965426, DOI: 10.1038/s41537-025-00581-6.Peer-Reviewed Original ResearchCitationsAltmetricConceptsClinical high riskSchizophrenia ProgramClinical high-risk cohortClinical high-risk stateResting-state fMRIFMRI scanningStudy of individualsNeuroimaging resultsBrain regionsNeuroimaging dataNeuroimaging protocolsStructural scansParticipation varianceDiffusion scansFMRIPercentage of participantsNeuroimagingVariance component analysisMulti-siteParticipantsPsychosisVarianceTime pointsDiffusion-weighted imagingHigh risk
Clinical Trials
Current Trials
Brain Network Changes Accompanying and Predicting Responses to Pharmacotherapy in OCD
HIC ID2000023688RoleSub InvestigatorPrimary Completion Date07/31/2024Recruiting ParticipantsGenderBothAge18 years - 65 years
Get In Touch
Copy Link